Table 1 Clinical characteristics of tumors and experiments in which corresponding xenografts were used
From: Origin of the vasculature supporting growth of primary patient tumor xenografts
Primary site description | ID# | Exp | Sex | Age | Histology description | Grade | Path T | Path N | Path M | AJCC stage path | Treatment prior to sample |
|---|---|---|---|---|---|---|---|---|---|---|---|
Esophagus, lower third | 12944 | 2 | M | 70 | Ad, NOS | III | 2 | 1 | 0 | 2B | no |
Esophagus, lower third | 13176 | 2 | M | 40 | Ad, NOS | III | 1 | 1 | 1 | 4 | no |
Ovary | 13575 | 2 | F | 67 | PSC | III | 3C | 0 | 0 | 3C | Carboplatin/Taxol |
Esophagus | 13618 | 2 | nd | nd | nd | nd | nd | nd | nd | nd | nd |
Ovary | 13987 | 2 | F | 43 | SSPC | III | 3C | 1 | 0 | 3C | no |
Pleura, NOS | 14967 | 4 | M | 70 | Meso | nd | 3 | 0 | 0 | 3 | Radiation and chemotherapy (Alimta & cisplatin) |
Pancreas, head of | 15010 | 3 | F | 74 | Inf Duct, NOS | II | 3 | 1 | 0 | 2B | no |
Pancreas, body of | 15406 | 3 | M | 74 | Inf Duct, NOS | II | 2 | 0 | 0 | 1B | no |
Kidney, NOS | 15773 | 3 | M | 69 | RCC, NOS | III | 3A | 0 | 1 | 4 | no |
Kidney, NOS | 15818 | 3 | F | 57 | RCC, Clear cell | III | 1B | 0 | X | 1 | no |
Lung, upper lobe | 15946 | 3 | F | 73 | SCC, NOS | III | 2 | 0 | 0 | 1B | no |
Pancreas, tail of | 16096 | 3 | M | 66 | Inf Duct, NOS | II | 2 | 0 | 0 | 1B | no |
Colon, ascending | 16115 | 3 | M | 59 | Ad, NOS | II | X | X | nd | nd | FOLFOX with Avastin |
Kidney, NOS | 16616 | 3 | M | 62 | RCC, NOS | III | 3B | 0 | 0 | 3 | no |
Kidney, NOS | 16692 | 2, 3 | M | 57 | RCC, sarcomatoid | IV | 3B | 1 | X | 4 | no |
Kidney, NOS | 16803 | 3 | M | 63 | RCC, Clear cell | III | 1A | X | X | 1 | no |
Colon, ascending | 16811 | 3 | F | 83 | Ad, NOS | II | 4 | 0 | 0 | 2B | no |
Pancreas, head of | 16870 | 3 | F | 31 | Inf Duct, NOS | III | 3 | 1 | 0 | 2B | no |
Colon, Sigmoid, NOS | 16879 | 3 | F | 76 | Ad, NOS | II | 3 | 0 | 0 | 2A | no |
Pancreas, head of | 17123 | 3 | M | 79 | Ad, NOS | III | 3 | 1 | 0 | 2B | no |
Rectosigmoid junction | 17224 | 2 | F | 52 | Ad, NOS | II | 3 | 1 | 1 | 4 | no |
Lung, lower lobe | 17228 | 3 | F | 82 | CSC | III | 2 | 0 | 0 | 1B | no |
Colon, ascending | 17239 | 2 | M | 71 | Ad, NOS | II | 3 | 2 | 0 | 3C | no |
Lung, upper lobe | 17246 | 2, 3 | M | 53 | Ad, NOS | III | 3 | 0 | 0 | 2B | no |
Lung, lower lobe | 17291 | 1, 3 | F | 53 | Pleomorphic ca | IV | 3 | 0 | nd | 2B | no |
Tonsillar pillar | 17307 | 2 | M | 67 | SCC, NOS | I | 0 | 2B | 1 | 4C | no |
Rectosigmoid junction | 17346 | 3 | M | 57 | Ad, NOS | II | 3 | 0 | nd | 2A | no |
Lung, lower lobe | 17448 | 2, 3 | M | 71 | Ad-SCC | II | 2 | 0 | X | 1B | no |
Colon, splenic flexure | 17641 | 1, 2, 3 | F | 59 | Ad, NOS | II | X | X | nd | nd | FOLFIRI & Avastin, Erbitux, irinotecan then oxaliplatin & Xeloda then SAHA, 5-FU and leucovorin. |
Cecum | 17651 | 3 | F | 74 | NE | n.d. | 4 | 1 | X | 4 | no |
Rectosigmoid junction | 18023 | 4 | F | 46 | Ad, Mucinous | II | X | X | nd | nd | Avastin and FOLFOX then Xeloda and Avastin |
Pancreas, overlapping lesion | 18254 | 1, 2 | F | 69 | Inf Duct, NOS | III | 3 | 1 | X | 2B | no |
Floor of mouth, NOS | 18316 | 2 | F | 47 | SCC, krt | I | X | X | nd | nd | Cisplatin and Taxotere |
Duodenum | 18484 | 2 | M | 77 | Ad, NOS | II | 4 | 1 | 0 | 3 | no |
Pancreas, head of | 18643 | 2 | F | 56 | Inf Duct, NOS | I | 3 | 1 | 0 | 2B | Chemoradiation: total of 5040 cGy with gemcitabine |
Pancreas, overlapping lesion | 19632 | 2 | F | 78 | Inf Duct, NOS | III | 3 | 0 | nd | 2A | no |
Palate, soft, NOS | 19785 | 5 | M | 65 | SCC, lg cell, nonkrt | III | 0 | 0 | X | nd | Induction chemotherapy |